In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Early effects of Sacubitril/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction.

Session Poster Session 2

Speaker Giuseppe Vitale

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Treatment
  • Session type : Poster Session

Authors : G Vitale (Palermo,IT), S Sarullo (Palermo,IT), C Nugara (Palermo,IT), F M Sarullo (Palermo,IT)

Authors:
G Vitale1 , S Sarullo2 , C Nugara1 , F M Sarullo1 , 1Buccheri La Ferla Fatebenefratelli Hospital - Palermo - Italy , 2University of Palermo - Palermo - Italy ,

Citation:

Introduction. Sacubitril/valsartan in patients with heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF.

Purpose. Our aim was to evaluate the cardiopulmonary effect of sacubitril/valsartan HFrEF patients.

Methods. In this observational study 94 patients with HFrEF underwent serial cardiopulmonary tests (CPET)  after initiation of sacubitril/valsartan in addition to recommended therapy.

Results. At baseline, 38% of patients had New York Heart Association (NYHA) class III HF, mean left ventricular ejection fraction (LVEF) was 27 ± 6%. After a mean follow-up of 7.4 ± 3.6 months systolic blood pressure decreased from 117±14 mm Hg to 101±12 mm Hg (p< .0001); Peak oxygen consumption (VO2) improved from 14.7±3.3 mL/kg/min at baseline (% of predicted = 54.2±14)  to 17.3±4.7 mL/kg/min after follow-up (% of predicted = 65.3±17.6) (p< .001), oxygen pulse increased from 11.6±2.9 at baseline to 13.7±4.2 mL/kg/min at follow-up (p< .001). VE/VCO2 Slope decreased from 34±6.3 to 31.9±6 (p= .024).

Conclusion. In ambulatory patients with HFrEF, administration of sacubitril/valsartan improved exercise tolerance, peak oxygen consumption and ventilatory efficiency at 7.4 ± 3.6  months follow-up. Further studies are necessary to better clarify underlying mechanisms of this functional improvement.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are